Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study.

Kang JI, Park HJ, Kim SJ, Kim KR, Lee SY, Lee E, An SK, Kwon JS, Lee JD.

Schizophr Bull. 2014 May;40(3):548-57. doi: 10.1093/schbul/sbt052. Epub 2013 Apr 15.

2.

Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results.

Klumpers UM, Veltman DJ, Drent ML, Boellaard R, Comans EF, Meynen G, Lammertsma AA, Hoogendijk WJ.

Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):565-74. doi: 10.1007/s00259-009-1292-9. Epub 2009 Nov 5.

PMID:
19890631
3.

Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.

de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X, León-Ortiz P, Rodríguez-Mayoral O, Solís-Vivanco R, Favila R, Graff-Guerrero A, Shungu DC.

Int J Neuropsychopharmacol. 2015 Sep 12;19(3):pyv105. doi: 10.1093/ijnp/pyv105.

4.

Biological evaluation of 2'-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET.

Mitterhauser M, Wadsak W, Wabnegger L, Mien LK, Tögel S, Langer O, Sieghart W, Viernstein H, Kletter K, Dudczak R.

Nucl Med Biol. 2004 Feb;31(2):291-5.

PMID:
15013496
5.

Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography.

Hasler G, Nugent AC, Carlson PJ, Carson RE, Geraci M, Drevets WC.

Arch Gen Psychiatry. 2008 Oct;65(10):1166-75. doi: 10.1001/archpsyc.65.10.1166.

PMID:
18838633
6.

In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients.

Frankle WG, Cho RY, Prasad KM, Mason NS, Paris J, Himes ML, Walker C, Lewis DA, Narendran R.

Am J Psychiatry. 2015 Nov 1;172(11):1148-59. doi: 10.1176/appi.ajp.2015.14081031. Epub 2015 Jul 2.

7.

Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder.

Geuze E, van Berckel BN, Lammertsma AA, Boellaard R, de Kloet CS, Vermetten E, Westenberg HG.

Mol Psychiatry. 2008 Jan;13(1):74-83, 3. Epub 2007 Jul 31.

PMID:
17667960
8.

Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects.

Frankle WG, Cho RY, Narendran R, Mason NS, Vora S, Litschge M, Price JC, Lewis DA, Mathis CA.

Neuropsychopharmacology. 2009 Feb;34(3):624-33. doi: 10.1038/npp.2008.104. Epub 2008 Jul 9.

9.

Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography.

Künig G, Leenders KL, Sanchez-Pernaute R, Antonini A, Vontobel P, Verhagen A, Günther I.

Ann Neurol. 2000 May;47(5):644-8.

PMID:
10805336
10.

Positron emission tomography measures of benzodiazepine receptors in Huntington's disease.

Holthoff VA, Koeppe RA, Frey KA, Penney JB, Markel DS, Kuhl DE, Young AB.

Ann Neurol. 1993 Jul;34(1):76-81.

11.

Decreased GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase deficiency.

Pearl PL, Gibson KM, Quezado Z, Dustin I, Taylor J, Trzcinski S, Schreiber J, Forester K, Reeves-Tyer P, Liew C, Shamim S, Herscovitch P, Carson R, Butman J, Jakobs C, Theodore W.

Neurology. 2009 Aug 11;73(6):423-9. doi: 10.1212/WNL.0b013e3181b163a5.

12.

In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat.

Dedeurwaerdere S, Gregoire MC, Vivash L, Roselt P, Binns D, Fookes C, Greguric I, Pham T, Loc'h C, Katsifis A, Hicks RJ, O'Brien TJ, Myers DE.

Eur J Nucl Med Mol Imaging. 2009 Jun;36(6):958-65. doi: 10.1007/s00259-009-1066-4. Epub 2009 Feb 10.

PMID:
19205698
13.
14.

Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT.

Kugaya A, Sanacora G, Verhoeff NP, Fujita M, Mason GF, Seneca NM, Bozkurt A, Khan SA, Anand A, Degen K, Charney DS, Zoghbi SS, Baldwin RM, Seibyl JP, Innis RB.

Biol Psychiatry. 2003 Oct 15;54(8):792-9.

PMID:
14550678
15.

Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia.

Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, Lucey JV, Kerwin RW.

Am J Psychiatry. 1997 Jan;154(1):56-63. Erratum in: Am J Psychiatry 1997 May;154(5):722.

PMID:
8988959
16.

PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia.

Karlsson P, Farde L, Halldin C, Sedvall G.

Am J Psychiatry. 2002 May;159(5):761-7.

PMID:
11986129
17.

Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder.

Dean B, Scarr E, McLeod M.

Brain Res Mol Brain Res. 2005 Aug 18;138(2):145-55.

PMID:
15950312
18.

Biological properties of 2'-[18F]fluoroflumazenil for central benzodiazepine receptor imaging.

Chang YS, Jeong JM, Yoon YH, Kang WJ, Lee SJ, Lee DS, Chung JK, Lee MC.

Nucl Med Biol. 2005 Apr;32(3):263-8.

PMID:
15820761
19.

Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task.

Suridjan I, Rusjan P, Addington J, Wilson AA, Houle S, Mizrahi R.

J Psychiatry Neurosci. 2013 Mar;38(2):98-106. doi: 10.1503/jpn.110181.

20.

Benzodiazepine receptor binding and schizophrenia.

Verhoeff NP.

Am J Psychiatry. 1997 Oct;154(10):1480. No abstract available.

PMID:
9326849

Supplemental Content

Support Center